2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司 两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。前沿生物将负责其中一款产品在中 国的I期临床试验推进，并完成另一款产品的IND支持性研究。 小核酸领域再迎重磅BD（商务拓展）交易。 作为交易对价，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并在两个项目中累计获得最高9.5亿美元的基于成 功开发、监管及商业化里程碑的付款，同时享有两款产品全球净销售额的分级特许权使用费。 有业内人士向21世纪经济报道记者指出，当前全球小核酸领域交易持续升温，这笔近10亿美元合作有望改善前沿生物现金流、支撑 研发与平台升级，成为其2020年上市以来持续亏损背景下的重要发展拐点，"不过相较于确定性首付款，后续里程碑兑现情况需持续 跟踪"。 受此利好消息提振，作为春节假期后的首个交易日，前沿生物股价在2月24日早盘高开，截至午间休盘报24.54元/股，上涨8.58%，总 ...

21世纪经济报道记者韩利明 小核酸领域再迎重磅BD（商务拓展）交易。 2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司 两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。前沿生物将负责其中一款产品在中 国的I期临床试验推进，并完成另一款产品的IND支持性研究。 作为交易对价，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并在两个项目中累计获得最高9.5亿美元的基于成 功开发、监管及商业化里程碑的付款，同时享有两款产品全球净销售额的分级特许权使用费。 有业内人士向21世纪经济报道记者指出，当前全球小核酸领域交易持续升温，这笔近10亿美元合作有望改善前沿生物现金流、支撑 研发与平台升级，成为其2020年上市以来持续亏损背景下的重要发展拐点，"不过相较于确定性首付款，后续里程碑兑现情况需持续 跟踪"。 受此利好消息提振，作为春节假期后的首个交易日，前沿生物股价在2月24日早盘高开，截至午间休盘报24.5 ...

证券研究报告·宏观报告·宏观周报 金融产品周报 20260207 海外市场流动性有企稳迹象，情绪或会好转 【勘误版】 [Table_Summary] 基金规模统计：（2026.2.2-2026.2.6） 市场行情展望：（2026.2.9-2026.2.13） 基金配置建议： 2026 年 02 月 24 日 《商品流动性冲击之后，哪些品种被 "错杀"？》 2026-02-04 《黄金 ETF，2026 年 1 月复盘与 2 月 证券分析师 芦哲 展望》 执业证书：S0600524110003 luzhe@dwzq.com.cn 证券分析师 唐遥衎 2026-02-03 执业证书：S0600524120016 东吴证券研究所 1 / 20 tangyk@dwzq.com.cn 相关研究 请务必阅读正文之后的免责声明部分 [Table_Tag] ◼ 权益类 ETF 基金规模变化统计：规模变化排名前三名的权益类 ETF 类 型分别为：规模指数 ETF（154.06 亿元），跨境行业指数 ETF（66.24 亿 元），策略指数 ETF（53.71 亿元）；基金规模变化排名后三名的权益 类 ETF 类型分别为：跨境规模 ...

五震荡走低，险守二十天线。恒指随外围低开 132 港股回顾 点，跌幅随即扩大至 247 点，低见 23730 点，其后跌幅 一度收窄至仅 20 点，午后大盘走势偏软，尾盘沽压再 度扩大。截至收盘，恒指收报 23831 点，下跌 145 点或 0.61%；国指收报 9656 点，下跌 47 点或 0.49%，大市 成交进一步减至 827.99 亿。港股通录得净流入资金 4.84 亿，其中港股通(沪)净流入 2.83 亿，港股通(深)净 流入 2.01 亿。板块方面，本地地产、软件、5G 概念板 块跌幅靠前；黄金股逆市走强。 周一港股三大指数全天强势震荡，恒生指数收涨 2.53%报 27081.91 点，恒生科技指数涨 3.34%报 5385.35 点，恒生中国企业指数涨 2.65%报 9197.38 点。大市成交 1730 亿港元。科技龙头、 半导体、有色股表现亮眼，紫金矿业、美团、中 芯国际涨超 5%，涨幅位居恒指成分股前列。新能 源汽车股普涨，蔚来涨近 6%，比亚迪股份涨近 5%。行业方面，恒生原材料业指数大涨 4.27%， 赣锋锂业涨超 8%，紫金黄金国际、五矿资源涨近 7%。大模型概念股回落，智谱跌近 ...

Core Insights - The breast cancer treatment field is experiencing significant advancements in 2025, characterized by the launch of numerous new drugs and clinical breakthroughs [2][18] Group 1: Milestone Breakthroughs - In January 2025, AstraZeneca and Daiichi Sankyo's HER2 ADC, Enhertu (T-DXd), received FDA approval for HR+/HER2 low-expressing advanced breast cancer as a second-line treatment, extending treatment lines [3] - Enhertu also gained FDA approval in December for use with pertuzumab in first-line treatment of unresectable or metastatic HER2-positive breast cancer, achieving a median PFS of over 40 months and reducing the risk of disease progression or death by 44% [3] - AstraZeneca's Capivasertib became the first AKT inhibitor approved in China for breast cancer patients with PIK3CA/AKT1/PTEN alterations, providing new treatment options [3][4] Group 2: New Drug Approvals - In May, Rongchang Bio's RC48 was approved as the first ADC for HER2-positive breast cancer with liver metastasis, addressing a gap in standardized treatment [7] - In September, Eli Lilly's oral SERD, Inluriyo (imlunestrant), was approved for ER+/HER2-negative breast cancer patients previously treated with endocrine therapy, marking it as the second oral SERD on the market [7] - In December, Zhenhua Tianqing's Kumosili capsules were approved for use with fulvestrant in HR+/HER2- locally advanced or metastatic breast cancer, becoming the first CDK2/4/6 inhibitor [8] Group 3: Breakthrough Research Outcomes - Roche's Giredestrant demonstrated significant clinical results in the evERA BC and lidERA BC studies, filling a gap in oral SERD treatment for HR+/HER2- early breast cancer and showing a 3-year IDFS rate of 92.4% [9][10] - Giredestrant is designed to cover all treatment stages of ER+ breast cancer, aiming to replace existing endocrine therapies and serve as a backbone for combination therapies [10] - AstraZeneca's T-DXd showed promising results in the DESTINY-Breast studies, with a 3-year IDFS of 92.4%, outperforming existing standard treatments [13][14] Group 4: New Targets and Mechanisms - The exploration of new targets and mechanisms in breast cancer treatment is gaining momentum, with PROTAC technology emerging as a promising approach for targeting undruggable proteins [14] - Vepdegestrant, a PROTAC drug, is under FDA review for ESR1 mutation-positive ER+/HER2- breast cancer, potentially becoming the first PROTAC drug approved [15] - The PD-L1/VEGF dual antibody Pumitamig showed a 68% cORR in a global study for locally advanced or metastatic triple-negative breast cancer [16][17]

截至11:07，港股通创新药ETF(159570)标的指数热门股多数回调：石药集团、中国生物制药、三生制药、翰森制药、荣昌生物跌超5%，信达生物跌超4%， 康方生物跌超3%。 | 序号 | 代码 | 名称 | 估算板車 | 涨跌幅 | 17.47 80 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 1801 | 信达生物 | 10.51% | -0.56% | 6.81亿 | | 2 | 1093 | 石药集团 | 12.18% | -3.15% | 5.98 7. | | 3 | 6160 | 高密被田 | 10.99% | -1.13% | 2.83 Z | | 4 | 1530 | 三生制药 | 6.50% | -2.57% | 2.65 Z | | 5 | 9926 | 康方生物 | 8.49% | -1.33% | 2.57 Z | | 6 | 3692 | 翰森制药 | 6.84% | -1.84% | 1.99 Z | | 7 | 1177 | 中国生物制药 | 10.01% | -3.66% | 1.74Z | | 8 | 6990 | 科伦博 ...

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **Pharmaceutical (Pharma)** and **Biopharmaceutical/Biotech** sectors, highlighting companies with potential for value re-evaluation and those entering a performance ramp-up phase [1][2]. Core Insights and Arguments 1. **Value Re-evaluation of Pharma Companies**: - There is a recommendation to further support Pharma companies that have the potential for value re-evaluation, particularly emphasizing key marginal changes. The BD (Business Development) revenue for Pharma is expected to normalize, which will drive an upward shift in the valuation framework [1][2]. 2. **Performance Ramp-up in Biopharma/Biotech**: - Continuous recommendation for Biopharma/Biotech companies that are entering a performance ramp-up phase and have pipelines that are consistently delivering results. The expectation is that by 2026, leading Biopharma/Biotech companies will enter a period of accelerated performance [2]. 3. **Key Marginal Changes**: - The core marginal change driving the value re-evaluation logic for Pharma companies is the normalization of BD revenue. This is supported by two main factors: - Leading Pharma companies have a more comprehensive technology platform and pipeline layout, enhancing their ability to continuously produce BD assets [2]. - External transactions are evolving from sporadic single-asset licensing to a more platform-based and series-based licensing model, making upfront payments, milestones, and revenue sharing more replicable and predictable. Recent collaborations, such as the partnership between **Shiyao** and **AstraZeneca** for a long-acting weight loss drug (total package of $18.5 billion) and **Innovent** with **Eli Lilly** in oncology and immunology (total package of $8.9 billion), exemplify this trend [2]. Recommendations - Specific companies recommended for investment include: - **Hengrui Medicine** - **Hansoh Pharmaceutical** - **Shiyao Group** (new addition in February) - **China National Pharmaceutical Group** - **Sinopharm** (new addition in February) - **Haisco** [2]. Additional Important Insights - The oncology, metabolism, and autoimmune sectors are expected to see a concentration of critical data releases. The integration of new technology platforms such as small nucleic acids, bispecific/trispecific antibodies, next-generation ADCs, and PROTAC/molecular glue is anticipated to provide significant valuation elasticity for leading companies at key data points, potentially opening up overseas BD opportunities [3].

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

Market Performance - On February 23, the Hang Seng Index rose by 668 points (2.5%) to close at 27,081 points, surpassing the 27,000 mark[1] - The Hang Seng Technology Index increased by 173 points (3.3%) to close at 5,385 points[1] - Daily trading volume in the Hong Kong market reached HKD 173 billion[1] US Market Reaction - The Dow Jones Index fell by 821 points (1.6%) to close at 48,804 points[2] - The Nasdaq Index decreased by 258 points (1.1%) to close at 22,627 points[2] - The S&P 500 Index dropped by 71 points to close at 6,837 points[2] Geopolitical and Economic Factors - Tensions in geopolitics led to a rise in international gold prices, which reached USD 5,100[1][2] - Trump's announcement of a 15% tariff increase on global imports following the Supreme Court's decision has created market uncertainty[1][2] Sector Performance - The automotive sector saw a rise of 2%-5% across most stocks, with over 9 million vehicles exported from mainland China[4] - The healthcare sector, represented by the Hang Seng Healthcare Index, increased by 1.6%[4] - Notable stock movements included a 5.4% rise for劲方生物 (2595 HK) and a 2.9% increase for中国生物制药 (1177 HK)[4] Domestic Travel Trends - Domestic travel orders on the 飞猪 platform for the 2026 Spring Festival increased by over 80% year-on-year, with hotel bookings up by 75%[3] - Popular theme park and attraction packages saw a 140% increase in order volume compared to the previous year[3]

小核酸药物赛道再添重磅国际合作。 2月23日晚间，前沿生物（688221）公告，公司已于2月16日与跨国药巨头葛兰素史克（GSK）签署独家授权协议，将旗下两款小核酸（siRNA）在研产品 的全球权益授予GSK。 分工明确 权益清晰 根据公告，此次授权的两款产品中，一款候选药物已进入新药临床试验申请（IND）阶段，另一款处于临床前阶段。 根据协议，前沿生物将负责其中一款产品在中国的I期临床试验推进，以及另一款产品的IND支持性研究；GSK则将主导两款产品后续的全球临床开发、 注册申报及商业化工作。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并有望在后续开发、监管和商业化过程中获得最高9.5亿美元的里程碑付 款，交易总金额累计超过10亿美元。此外，前沿生物还将享有两款产品全球净销售额的分级特许权使用费。 前沿生物在公告中表示，此次合作不仅将为公司带来可观的现金流支持，助力核心研发投入与技术平台升级，也标志着其在小核酸药物领域的技术实力获 得国际认可。公司在此次合作中将借助GSK在全球临床开发与商业化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业化、拓 展全球 ...